Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
An open-label, non-randomized pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with severe renal impairment
• To investigate the effect of severe renal impairment on the pharmacokinetics of FF and GW642444 following repeat administration of FF/ GW642444M (200/25mcg)via NDPI
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development
MAJ Il y a 4 ans
A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 male and female subjects, aged 18 to 70 years with type 2 diabetes mellitus who are treatment naïve
The present study is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 and pioglitazone 30mg, compared to placebo, administered as monother...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
Ofatumumab retreatment and maintenance treatment in patients with CLL
To estimate the proportion of objective responders over 52 weeks to ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL)who progressed following ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
Randomised, double-blind, placebo-controlled study of topical GW842470X formulation in adult patients with moderate atopic dermatitis
To investigate clinical efficacy of 3% GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A study to test the effectiveness and safety of inhaled GSK2269557 – a potential new medicine for asthma
To investigate the efficacy of inhaled GSK2269557 administered once daily for 28 days in subjects with persistent uncontrolled asthma, compared with placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis
To assess the anti-inflammatory efficacy of rosiglitazone XR 8 mg administered once daily for a period of 6 months to subjects with rheumatoid arthritis who demonstrate active disease despite disease-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Stage III and IVA,B Squamous Cell Carcinoma of the Head and Neck (SCCHN)
To evaluate and explore the activity of lapatinib or placebo in the two treatment groups with respect to the complete response rate (per RECIST) at six months (24 weeks) from chemoradiation completion...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A study to compare triple therapy versus dual therapy in patients with asthma
To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic Rhinitis
The primary objective of this study is to compare the efficacy and safety of GW685698X 100 mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (≥ ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
Phase I • To determine the safety and tolerability of pazopanib and lapatinib when administered in combination with EIAC in patients with recurrent Grade III or IV malignant gliomas. • To determine t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant